Aprea Therapeutics financials
$0.7696+2.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $285.8K | $1.5M | $583.2K | $0.00 | $0.00 | — | — |
| Gross profit | $285.8K | $1.5M | $583.2K | $0.00 | $0.00 | — | — |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M | -$52.8M | -$29.5M |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M |
| Net margin | −4409.2% | −862.4% | −2449.6% | — | — | — | — |
| Diluted EPS | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-34.88 | $-50.61 | $-93.40 |
| EBITDA | -$13.2M | -$14.3M | -$15.5M | -$113.2M | -$37.2M | -$52.6M | -$29.5M |
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M | -$41.8M | -$26.7M |
| Free cash flow | -$12.9M | -$13.6M | -$12.3M | -$25.0M | -$37.7M | -$41.8M | -$26.7M |
| Diluted shares | 6.5M | 5.5M | 3.6M | 1.7M | 1.1M | 1.1M | 0.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M | $89.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $2.4M | $0.00 | $0.00 |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M | $92.8M |
| Total liabilities | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M | $15.4M |
| Shareholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M | $77.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology